Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2018. november 14., szerda 09:26 |
Grünenthal acquires Averitas Pharma and establishes commercial footprint in the US |
|
Aachen, Germany / Morristown, New Jersey, USA, 14 November, 2018 (APA/OTS) - Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics. |
"I am proud to say that we are now establishing our own commercial
presence in the world's biggest pharma market, the US, for the first
time," says Gabriel Baertschi, Grünenthal's Chief Executive Officer.
"This acquisition is another important milestone in executing our
growth strategy and expanding our business across multiple pain
related therapeutic categories and geographies. Averitas Pharma is a
perfect match due to its significant specialty pharma expertise in
the US market and experience in different commercial models also
beyond the typical 'reach and frequency' approach".
Averitas Pharma will be enhancing the commercial distribution model
for Qutenza® towards a specialty pharmacy and hub services model
that makes it easier for patients to access the product and support
health care professionals in prescribing and applying it. "This will
help us transitioning and ramping up the Qutenza® US business,
bringing the product back on the growth path in the US," explains
Gabriel Baertschi.
Qutenza® is a local analgesic and an alternative to the current
standard of care, as there is still a high unmet medical need in
pain management, particularly for non-opioid and non-systemic
treatments. In Europe, it is approved for a broad peripheral
neuropathic pain indication in adults, e.g. post-surgical
neuropathic pain, cancer-related neuropathic pain and painful
diabetic peripheral neuropathy. In the US, Qutenza® is currently
only approved for the treatment of postherpetic neuralgia (PHN).
Averitas Pharma will work towards a broader neuropathic pain label
from the US Food & Drug Administration (FDA).
Grünenthal continues executing its growth strategy and has been
expanding its pain portfolio by a series of acquisitions including
European rights to Nexium®, the global (ex US and Japan) rights to
Vimovo®, the global rights to Qutenza® and global (ex Japan) rights
to Zomig®. The company has signed deals with a total value of more
than US$ 1.3 billion since 2016.
About Qutenza® Qutenza® (capsaicin) 8% patch is approved in the US for the
management of neuropathic pain associated with postherpetic
neuralgia. A single, 1-hour, localized treatment with Qutenza® may
provide 3 months of relief from post-shingles nerve pain (PHN). In
Europe, Qutenza® is approved by the European Medicines Agency for
the treatment of peripheral neuropathic pain in adults, including
post-surgical neuropathic pain, cancer-related neuropathic pain and
painful diabetic peripheral neuropathy, either alone or in
combination with other pain medicines. The 8% capsaicin patch
delivers a high dose of capsaicin directly to the damaged nerves in
the skin that are the source of neuropathic pain. Applied to the
area of pain, the capsaicin reduces the spontaneous activity and
consequently reduces the neuropathic pain intensity. Important
safety information can be found here: www.qutenza.com and
www.ema.europa.eu/documents/product-information/qutenza-epar-product-information_en.pdf
About Grünenthal Grünenthal is an entrepreneurial, science-based pharmaceutical
company specialized in pain, gout and inflammation. Our ambition is
to deliver four to five new products to patients in diseases with
high unmet medical need by 2022 and become a € 2 bn company. We are
a fully integrated research & development company with a long track
record of bringing innovative pain treatments and state-of-the-art
technologies to patients. By sustainably investing in our R&D above
the industrial average, we are strongly committed to innovation. Grünenthal is an independent, family-owned company headquartered in
Aachen, Germany. We are present in approx. 30 countries with
affiliates in Europe, Latin America and the US. Our products are
sold in more than 100 countries and approx. 5,200 employees are
working for Grünenthal worldwide. In 2017, Grünenthal achieved
revenues of approx. € 1.3 bn. More information: www.grunenthal.com
Follow us on: LinkedIn: Grunenthal Group Twitter: @grunenthalgroup Instagram: gruenenthal
For further information, please contact: Štěpán Kráčala, Head Global Communications Tel.: +49 241 569-1335, Stepan.Kracala@grunenthal.com Grünenthal GmbH, 52099 Aachen, Germany
Kerstin Nacken, Head Editorial Management and Media Relations Tel.: +49 241 569-2710, Kerstin.Nacken@grunenthal.com Grünenthal GmbH, 52099 Aachen, Germany
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|